November 23, 2016 - By Peter Erickson · 0 Comments
The stock of ACCUREXA INCORPORATED (OTCMKTS:ACXA) registered an increase of 361.54% in short interest. ACXA’s total short interest was 6,000 shares in November as published by FINRA. Its up 361.54% from 1,300 shares, reported previously. With 4,100 shares average volume, it will take short sellers 2 days to cover their ACXA’s short positions. The stock last traded at $0.55 per share. It is down 6.78% since April 21, 2016 and is downtrending. It has underperformed by 12.11% the S&P500.
Accurexa, Inc. is a development-stage company. The company has a market cap of $4.64 million. The Firm is focused on developing neurological therapies to be directly delivered into specific regions of the brain. It currently has negative earnings. The Firm is developing its ACX-31 program to deliver approximately two chemotherapy drugs, temozolomide in combination with biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) locally to brain tumor sites.
Accurexa, Inc. (Accurexa), incorporated on August 29, 2012, is a development-stage company. The Firm is focused on developing neurological therapies to be directly delivered into specific regions of the brain. The Firm is developing its ACX-31 program to deliver approximately two chemotherapy drugs, temozolomide in combination with biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) locally to brain tumor sites. Through its second development program, it is developing BranchPoint device that can deliver therapeutics through the radial deployment of a delivery catheter to large and anatomically complex brain targets through a single initial brain penetration. It is based on a neurosurgical delivery platform, which can enable approaches to neurological therapy and be modified for the delivery of a range of therapeutics, such as stem cells to treat neurodegenerative diseases, chemotherapeutics to brain tumors and gene therapy vectors.
More notable recent Accurexa Inc (OTCMKTS:ACXA) news were published by: Bizjournals.com which released: “It’s not brain surgery â€” well it is for Accurexa and Dr. Daniel Lim” on August 08, 2014, also Prnewswire.com with their article: “DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a …” published on September 07, 2016, Marketwired.com published: “”NEW TO THE STREET’s” October Line-Up Broadcast on FOX Business — Accurexa …” on October 03, 2016. More interesting news about Accurexa Inc (OTCMKTS:ACXA) were released by: Marketwired.com and their article: “”NEW TO THE STREET” Broadcasting on FOX Business, October 30, 2016, 1 PM …” published on October 25, 2016 as well as Finance.Yahoo.com‘s news article titled: “DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2017 Financial …” with publication date: November 14, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Peter Erickson